Sofia Dahoune
Investment Manager @ Elaia
Paris, France
Sofia Dahoune is a Series A investor at Elaia in Paris focused on Biotechnology and Power Grid. VC Investment Manager at Bpifrance
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Sofia Dahoune invests in
Stages Sofia Dahoune invests in
Countries Sofia Dahoune invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (40%)
- Power Grid 1 (20%)
- Life Science 1 (20%)
- Pharmaceutical 1 (20%)
- Machine Learning 1 (20%)
Stage
- Series A 2 (40%)
- Seed 1 (20%)
- Pre-Seed 1 (20%)
Country
- France 2 (40%)
- Luxembourg 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Graph Therapeutics
|
Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of people are leftwithout adequate treatment options - and AI trained with complex disease data can solve this. | $5M / Seed / Jun 22, 2026 | |
TerraSpark
|
TerraSpark Energy specializing in software solutions for renewable energy asset management. The product, TerraSpark Hub, provides comprehensive oversight of commercial and technical data for green energy assets like solar and wind projects. | $5.8M / Pre-Seed / Mar 30, 2026 | |
AQEMIA
|
AQEMIA is a pharmatech company developing a drug discovery platform to discover new drugs for specific therapeutic targets. Its platform combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a growing pipeline of new drug candidates. The company utilizes advanced techniques, including generative AIand atomic scale physics, to design novel drugs tailored for specific therapeutic targets. | $19.5M / Series A / Oct 19, 2022 | |
Alice & Bob
|
Alice&Bob build Universal, Error-free, Quantum Computers to help industries and researchers solve the hardest problems. | $29.9M / Series A / Mar 09, 2022 | |
|
AQEMIA
|
AQEMIA is a pharmatech company developing a drug discovery platform to discover new drugs for specific therapeutic targets. Its platform combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a growing pipeline of new drug candidates. The company utilizes advanced techniques, including generative AIand atomic scale physics, to design novel drugs tailored for specific therapeutic targets. | $10.8M / Series A / May 01, 2021 |
Co-Investors
About Elaia
Elaia is a European full stack tech and deep tech investor. We partner with ambitious entrepreneurs from inception to leadership, helping them navigate the future and the unknown. For over twenty years, we have combined deep scientific and technological expertise with decades of operational experience to back those building tomorrow. Our jointventure with Lazard, Lazard Elaia Capital, enables us to support exceptional founders at any stage. From our offices in Paris, Barcelona and Tel Aviv, we have been active partners with over 100 startups including Criteo, Mirakl, Shift Technology, AQEMIA and Alice & Bob.
Elaia Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Louisa Mesnard
CMO & Head of Sustainability
|
|||
Philippe Gire
Partner
|
|||
|
Sofia Dahoune
Investment Manager
|
|||
Anne-Sophie Carrese
Managing Partner
|
|||
|
Céline Passedouet
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sofia Dahoune invest in?
Sofia Dahoune invests primarily in Biotechnology, Power Grid and Life Science startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sofia Dahoune?
Public channels for Sofia Dahoune include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sofia Dahoune last invest?
The most recent investment recorded for Sofia Dahoune closed in Jun 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
